Data updated: Sep 20, 2026
GERD Clinical Trial Landscape
GERD is being studied across 150 clinical trials registered since 2008, with 19 programs currently active. The competitive pipeline includes 7 active Phase 3 trials, 2 active Phase 2 trials, and 4 active Phase 1 trials.
Top industry sponsors include Cinclus Pharma Holding AB, Onconic Therapeutics Inc., Phathom Pharmaceuticals, Inc..
Trial activity
19 active / 150 total since 2008
Active by phase 7 Ph3 / 47 2 Ph2 / 24 4 Ph1 / 45 6 Ph4 / 34
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Cinclus Pharma Holding AB 2 2 1
Onconic Therapeutics Inc. 2 1 0
Phathom Pharmaceuticals, Inc. 1 4 0
Addpharma Inc. 1 3 0
Daewoong Pharmaceutical Co. LTD. 1 1 0
HK inno.N Corporation 1 1 0
Valenta Pharm JSC 1 0 0
Carnot Laboratories 1 0 0
Takeda 0 11 2
AstraZeneca 0 10 0
Eisai Inc. 0 6 0
Reckitt Benckiser Healthcare (UK) Limited 0 3 1
Neutec Ar-Ge San ve Tic A.Ş 0 3 1
Chong Kun Dang Pharmaceutical 0 4 0
Bayer 0 3 0
How the field has grown
New-trial starts peaked in 2017 (10 registered); 2025 saw 10. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (15 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 6
2017 10
2018 8
2019 3
2020 4
2021 6
2022 4
2023 6
2024 7
2025 10
2026 4
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (3) 217
2017 (0) 0
2018 (4) 354
2019 (0) 0
2020 (0) 0
2021 (0) 0
2022 (1) 776
2023 (0) 0
2024 (0) 0
2025 (5) 140
2026 (2) 442
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT01696734 RECRUITING
Domperidone in Treating Patients With Gastrointestinal Disorders
M.D. Anderson Cancer Center n=200
NCT07037875 ACTIVE NOT RECRUITING
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Cinclus Pharma Holding AB n=500
NCT07160790 NOT YET RECRUITING
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
Onconic Therapeutics Inc. n=321
NCT07063576 RECRUITING
Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms
Adnan Imtiaj Rahul n=60
NCT07049315 NOT YET RECRUITING
Mandibular Advancement Devices for Reflux in Obstructive Sleep Apnea
Tuiuti University of Paraná n=40
NCT07732075 NOT YET RECRUITING
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis
Onconic Therapeutics Inc. n=384
NCT07752407 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Phathom Pharmaceuticals, Inc. n=500
NCT07310927 COMPLETED
Alginate vs Sucralfate for GERD Symptomatic Relief
CMH Lahore Medical College and Institute of Dentistry n=140
NCT07313774 WITHDRAWN
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Cinclus Pharma Holding AB
NCT01869491 COMPLETED
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
Reckitt Benckiser Healthcare (UK) Limited n=1,107
NCT01872897 COMPLETED
Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Reckitt Benckiser Healthcare (UK) Limited n=45
NCT05195528 COMPLETED
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phathom Pharmaceuticals, Inc. n=776
NCT02135107 COMPLETED
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Eisai Co., Ltd. n=517
NCT00838526 COMPLETED
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Eisai Inc. n=240
NCT03561090 TERMINATED
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Ironwood Pharmaceuticals, Inc. n=495
NCT03561883 COMPLETED
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Ironwood Pharmaceuticals, Inc. n=609
NCT03367195 TERMINATED
Efficacy and Safety of DLBS2411 in the Management of GERD
Dexa Medica Group n=32
NCT04080726 COMPLETED
Efficacy and Safety of HIP1601 Capsule
Hanmi Pharmaceutical Company Limited n=213
NCT01265550 COMPLETED
A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
VA Office of Research and Development n=366
NCT02954848 COMPLETED
Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
Takeda n=484
NCT02873689 COMPLETED
Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients
Takeda n=217
NCT03516188 COMPLETED
Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants
Universiti Sains Malaysia n=24
NCT00857597 TERMINATED
Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
University of Pittsburgh n=60
NCT02619747 TERMINATED
Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients
Reckitt Benckiser Healthcare (UK) Limited n=16
NCT02860624 COMPLETED
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Livzon Pharmaceutical Group Inc. n=550
NCT02623062 COMPLETED
Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study
Reckitt Benckiser Healthcare (UK) Limited n=644
NCT00658632 COMPLETED
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Eisai Inc. n=1,397
NCT00839306 COMPLETED
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Eisai Inc. n=240
NCT00911534 COMPLETED
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
Eisai Inc. n=305
NCT00734747 COMPLETED
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Aviel Roy-Shapira, M.D. n=72
NCT00728481 COMPLETED
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Mayo Clinic n=51
NCT00658775 COMPLETED
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Eisai Inc. n=1,069
NCT00658528 COMPLETED
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Eisai Inc. n=1,061
NCT01710462 WITHDRAWN
Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease
Eurofarma Laboratorios S.A.
NCT01753128 COMPLETED
Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn
Mahidol University n=83
NCT01474369 COMPLETED
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Takeda n=827
NCT01370538 COMPLETED
Efficacy of Esomeprazole in Patients With Frequent Heartburn
AstraZeneca n=341
NCT01370525 COMPLETED
Efficacy of Esomeprazole in Patients With Frequent Heartburn
AstraZeneca n=340
NCT00787891 COMPLETED
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. n=127
NCT01065649 COMPLETED
Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients
Universidade de Passo Fundo n=20
NCT01132638 COMPLETED
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
Takeda n=713
NCT01338077 COMPLETED
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
Chang Gung Memorial Hospital n=195
NCT01391715 WITHDRAWN
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD
Inje University
NCT01509261 COMPLETED
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
Il-Yang Pharm. Co., Ltd. n=292
NCT01400945 COMPLETED
Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease
Ahn-Gook Pharmaceuticals Co.,Ltd n=154
NCT00674245 COMPLETED
Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.
Southern Arizona VA Health Care System n=40
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only